Jaguar Health, Inc. — Form 8-K Summary
Reporting context: The report covers events dated September 30 and October 2, 2026, and was signed October 5, 2026. It reports financing amendments and a special preferred-stock dividend, not quarterly or annual operating results.
Financial obligations and liquidity
- Royalty interests: Jaguar amended royalty agreements with Uptown Capital and Streeterville Capital, each originally for $12 million. Monthly payments are deferred from October 1, 2026, to January 1, 2027. Thereafter, each monthly payment is the greater of $750,000 or the actual royalty payment due under the applicable agreement.
- Secured note: Jaguar and wholly owned subsidiary Napo Pharmaceuticals amended a Streeterville note originally issued with $6,220,812.50 principal. Its maturity was extended from October 1, 2026, to January 1, 2027. The filing does not state the current outstanding balance or other revised note terms.
- Operating and liquidity metrics: The filing provides no revenue, profit, cash flow, margin, cash-balance, or other current liquidity figures. It does not quantify the effect of the amendments on liquidity or total debt.
Preferred-stock dividend and security terms
- The board declared a one-time dividend of one Series R Convertible Preferred share for each common share outstanding on the October 13, 2026 record date, and for each share issuable upon exercise of specified eligible warrants covering up to 142,535 common shares. Payment was expected October 15; the Nasdaq ex-dividend date was to be announced.
- The company designated 2,325,000 Series R shares. Each share is scheduled to convert automatically on November 2, 2026, into five common shares, subject to adjustments and a 19.99% beneficial-ownership cap. Aggregate common shares issuable are capped at 11,625,000, subject to adjustment. Shares withheld by the cap may be held in abeyance.
- Series R has no dividends or ordinary voting rights, is junior to specified senior preferred stock in liquidation, and has no established or expected trading market. The filing states that no fractional shares will be issued and fractional entitlements will be rounded up.
- Series P investors consented to the dividend and Series R authorization. In consideration, Jaguar agreed that upon a defined Fundamental Transaction it would repurchase their then-outstanding Series P shares for cash at the applicable liquidation amount, to the extent legally available funds and subject to necessary approvals and consents.
Changes, outlook, and risks
The royalty-payment start dates and note maturity were each extended by three months. The amendments postpone these specified payment or maturity dates but do not eliminate the obligations; the royalty agreements also provide for a monthly minimum of $750,000 each once payments begin. The filing gives no financial forecast or management outlook. It references supplemental risk factors relating to the preferred-stock dividend in Exhibit 99.2, but their detailed contents are not included in the supplied filing text.
Important facts for investors to verify
- Current balances, collateral and other terms of the royalty interests and secured note, and the company’s ability to meet the January 2027 payment and maturity dates.
- The actual royalty amounts due under each agreement and the resulting combined monthly payment burden.
- Final dividend eligibility, the announced ex-dividend date, and the number of Series R shares distributed.
- Conversion mechanics, any shares held in abeyance under the 19.99% cap, and potential common-stock dilution within the 11,625,000-share limit.
- The full supplemental risk factors and the Series P liquidation amount and approvals applicable to a repurchase following a Fundamental Transaction.